Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + TNT in Resectable Low Rectal Cancer
NCT07561060Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in rectal cancer, sponsored by Fudan University. Primary endpoint: Complete Response rate at 12 months. Started Jan 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07561060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07561060.